Morgan Stanley’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-292,567
| Closed | -$1.32M | – | 8406 |
|
|
2025
Q2 | $1.32M | Sell |
292,567
-207,594
| -42% | -$933K | ﹤0.01% | 4963 |
|
|
2025
Q1 | $2.22M | Buy |
500,161
+179,354
| +56% | +$1.04M | ﹤0.01% | 4539 |
|
|
2024
Q4 | $2.51M | Buy |
320,807
+72,085
| +29% | +$878K | ﹤0.01% | 4549 |
|
|
2024
Q3 | $3.27M | Buy |
248,722
+45,582
| +22% | +$578K | ﹤0.01% | 4296 |
|
|
2024
Q2 | $2.45M | Buy |
203,140
+15,043
| +8% | +$203K | ﹤0.01% | 4421 |
|
|
2024
Q1 | $3.06M | Sell |
188,097
-302,193
| -62% | -$4.07M | ﹤0.01% | 4305 |
|
|
2023
Q4 | $3.34M | Buy |
490,290
+382,416
| +355% | +$2.21M | ﹤0.01% | 4642 |
|
|
2023
Q3 | $588K | Sell |
107,874
-22,748
| -17% | -$132K | ﹤0.01% | 5098 |
|
|
2023
Q2 | $887K | Sell |
130,622
-119,827
| -48% | -$898K | ﹤0.01% | 4901 |
|
|
2023
Q1 | $1.25M | Sell |
250,449
-43,514
| -15% | -$178K | ﹤0.01% | 4731 |
|
|
2022
Q4 | $1.43M | Buy |
293,963
+38,471
| +15% | +$279K | ﹤0.01% | 4665 |
|
|
2022
Q3 | $3.68M | Sell |
255,492
-118,664
| -32% | -$1.97M | ﹤0.01% | 3944 |
|
|
2022
Q2 | $5.66M | Sell |
374,156
-167,405
| -31% | -$1.95M | ﹤0.01% | 3653 |
|
|
2022
Q1 | $6.43M | Buy |
541,561
+251,177
| +86% | +$2.58M | ﹤0.01% | 3403 |
|
|
2021
Q4 | $4.71M | Buy |
290,384
+206,378
| +246% | +$4.41M | ﹤0.01% | 3783 |
|
|
2021
Q3 | $2.4M | Sell |
84,006
-8,160
| -9% | -$257K | ﹤0.01% | 4415 |
|
|
2021
Q2 | $3.11M | Sell |
92,166
-122,270
| -57% | -$3.92M | ﹤0.01% | 4251 |
|
|
2021
Q1 | $6.48M | Buy |
214,436
+82,151
| +62% | +$3.37M | ﹤0.01% | 3139 |
|
|
2020
Q4 | $6.55M | Buy |
132,285
+56,893
| +75% | +$2.63M | ﹤0.01% | 2970 |
|
|
2020
Q3 | $2.89M | Sell |
75,392
-6,559
| -8% | -$261K | ﹤0.01% | 3296 |
|
|
2020
Q2 | $3.54M | Buy |
81,951
+76,700
| +1,461% | +$2.9M | ﹤0.01% | 3029 |
|
|
2020
Q1 | $137K | Sell |
5,251
-241,850
| -98% | -$7.02M | ﹤0.01% | 5048 |
|
|
2019
Q4 | $7.72M | Buy |
247,101
+116,105
| +89% | +$3.44M | ﹤0.01% | 2703 |
|
|
2019
Q3 | $3.41M | Buy |
130,996
+130,718
| +47,021% | +$3.34M | ﹤0.01% | 3294 |
|
|
2019
Q2 | $6K | Sell |
278
-1,104
| -80% | -$25.4K | ﹤0.01% | 6282 |
|
|
2019
Q1 | $37K | Sell |
1,382
-9,584
| -87% | -$210K | ﹤0.01% | 5801 |
|
|
2018
Q4 | $223K | Buy |
10,966
+10,866
| +10,866% | +$250K | ﹤0.01% | 5235 |
|
|
2018
Q3 | $3K | Buy |
+100
| New | +$2.54K | ﹤0.01% | 6525 |
|
Other funds holding YMAB
Morgan Stanley's YMAB Position: Q3 2025 in Review
Morgan Stanley sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 292,567 shares — an estimated $1.32M sold.
Morgan Stanley first reported a position in YMAB in Q3 2018 and held it in 28 quarters. The position peaked at $7.72M in Q4 2019. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Morgan Stanley reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Morgan Stanley sold 292,567 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1.32M.
- Morgan Stanley first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 28 quarters.
- Morgan Stanley's Y-mAbs Therapeutics position peaked at $7.72M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.